Aquestive Therapeutics Inc AQST

Morningstar Rating
$4.57 +0.02 (0.44%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AQST is trading at a LOCK|pk!t# premium.
Price
$4.56
Fair Value
LOCK|%?#FG!x
Uncertainty
LOCK|#PN
1-Star Price
LOCK|!$&$>Kl
5-Star Price
LOCK|Hq@H%F
Economic Moat
LOCK|^nC
Capital Allocation
—

News

Trading Information

Previous Close Price
$4.55
Day Range
$4.46–4.61
52-Week Range
$2.93–7.55
Bid/Ask
$4.60 / $4.84
Shares Outstanding
125.51M
Market Cap
$573.59M
Volume/Avg
1M / 3M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
10.10
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
147

Valuation

Metric
AQST
Price/Earnings (Normalized)
—
Price/Book Value
—
Price/Sales
10.10
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
AQST
Quick Ratio
6.54
Current Ratio
7.19
Interest Coverage
−3.95
Quick Ratio
AQST

Profitability

Metric
AQST
Return on Assets (Normalized)
−41.38%
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
−843.10%
Return on Assets
AQST

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|kXz@cQ?LOCK|<S%F$67B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|@x<BzM^^LOCK|@rrX$46B
Haleon PLC ADR
HLN
LOCK|S$J?$@LOCK|Y>$38B
Zoetis Inc Class A
ZTS
LOCK|>TcFt%GLOCK|kp$29B
Viatris Inc
VTRS
LOCK|n@JKxcLOCK|#JP$20B
Elanco Animal Health Inc
ELAN
LOCK|d>LOCK|%XK$11B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|x^#WgWlLOCK|$P$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|f&#jL@QLOCK|lLh$7B
Prestige Consumer Healthcare Inc
PBH
LOCK|CSpg?gLOCK|NGD!$2B
Perrigo Co PLC
PRGO
LOCK|y?%%xrLOCK|j!$2B

Sponsor Center